Bococizumab is a humanized monoclonal antibody binding to proprotein convertase subtilisin/kexin type 9 (PCSK9), which reduces LDL cholesterol (LDL-C) levels. Bococizumab may be used as a potential drug for the treatment of hypercholesterolemia.
BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.